A novel taping therapy for depression: a report on three cases treated successfully with taping

Abstract

Purpose: To investigate the clinical feasibility of the Wheel Balance Cancer Therapy (WBCT) for refractory non-small cell lung cancer (rNSCLC) analyzed patients’ overall survival outcome. Methods: From October 4th 2004 to October 3rd 2013, the refractory NSCLC patients who first visited East West Cancer Center were reviewed. Following the study eligibility, overall survival and median survival of the 33 refractory NSCLC patients who treated with WBCT were statistically analyzed with Kaplan-Meier and Wilcoxon’s signed rank test. Results: Of total 33 patients, overall 1 year, 2years and the median survival were 78.8%, 42.4% and 20.3 months (95%CI:15.525.0). The median overall survival of WBT over 14days and under 28days, and over 28 days were 16.5 months (95%C I:12.8-20.2) and 25.4 months (95%CI:16.8-34.0) (p=0.280). The median overall survival of prior conventional treatment and non-conventional treatment were 22.8 months (95%CI:16.2-29.4) and 4.6 months (95%CI:1.9-7.4) (p=0.000). The median overall survival of under 65 years and over 65 years were 35.6 months (95%CI:16.5-54.7) and 16.5 months (95%CI:10.8-22.2) (p=0.012). The median overall survival of Eastern Cooperative Oncology Group (ECOG) score <3 and ECOG score ≥3 were 8.2 months (95%CI:3.5-13.0) and 2.5 months (95%CI:1.6-3.3) (p=0.004). Conclusion: Patients with prior conventional treatment, under 65 years and ECOG score <3 are more efficient to refractory NSCLC patients treated with WBCT. And this study also supports the safety of WBCT. Contact: Hwaseung Yoo, altyhs@dju.kr